Table I.

Inclusion and exclusion criteria

Inclusion criteria

Exclusion criteria

• ACS patients undergoing PCI and received at least 1 new-generation DES⁎ • Completed 9-12 m of DAPT (either with clopidogrel or ticagrelor on top of aspirin) after index PCI procedure • 18-85 y • Meet criteria of both high bleeding and ischemic risk†  - Patients <65 y old must meet at least 1 of clinical criteria of high bleeding risk and at least 1 of clinical criteria of high ischemic risk  - Patients 65-75 y old must meet 1 of clinical criteria of either high bleeding risk or high ischemic risk  - Patients ≥75 y old • Written informed consent

• Any interruption, abruption, or discontinuation on DAPT during the recent 6 m because of adverse events (hemorrhagic or ischemic) or other reasons • Planned surgery within 90 d • Planned coronary revascularization (surgical or percutaneous) within 90 d • Dialysis-dependent renal failure • Moderate to severe liver function dysfunction (ALT or AST >2 times upper limit of normal) • Life expectancy <1 y • Unable or unwilling to provide informed consent • Women of child-bearing potential • Platelet count <100,000/mm3 • Subjects on warfarin or other anticoagulant therapy

ACS, acute coronary syndromes; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention.

^⁎New-generation DESs refer to any DES with thin strut/Co-Cr alloy platform, or with biodegradable polymer/polymer free, or with more biocompatible drugs other than paclitaxel or sirolimus.

^†Criteria of high bleeding and ischemic risk; see Table II.